Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders
Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders
06/09/20, 10:34 AM
Location
san diegoMoney raised
$76 million
Industry
therapeutics
biotechnology
health care
Round Type
series b
Autobahn Therapeutics is launching to create the next generation of regenerative medicines to restore hope for people affected by CNS disorders. The company has completed a $76 million Series B fundraising co-led by ARCH Venture Partners and Cowen Healthcare Investments, with participation from BVF Partners L.P., Biogen, Bristol Myers Squibb, Pfizer Ventures, Invus, Section 32, Samsara BioCapital and Alexandria Venture Investments. Proceeds will be used to advance Autobahn’s lead program candidate, ABX-002, a thyroid hormone receptor beta agonist therapy for the treatment of multiple sclerosis (MS) and adrenomyeloneuropathy (AMN), a rare genetic disorder, and a portfolio of transformational CNS programs leveraging the company’s brain-targeting chemistry platform.
Company Info
Location
san diego, california, united states
Additional Info
Autobahn Therapeutics is focused on restoring hope for people affected by CNS disorders. Leveraging its proprietary brain-targeting chemistry platform, Autobahn aims to unlock new therapeutic opportunities through precision tuning of the central exposure of its molecules. The company’s pipeline is led by ABX-002, a thyroid hormone receptor beta agonist, being developed initially for people with treatment-resistant depression. Autobahn Therapeutics is based in San Diego.